FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (1:1) w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid

FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (1:1) w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid

FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (1:1) w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration. L-Glutamine and sodium bicarbonate are omitted so researchers can supplement precisely to their protocol.

• Quadruple-stage filtration: 0.1 µm ×2 (Prefiltration I & II) + 0.04 µm ×2 (Final filtration I & II — Polish), reaching a 0.04 µm final cut-off
• Endotoxin release specification: < 0.05 EU/mL (LAL assay, USP <85> BET), tested per manufacturing batch
• DMEM/F-12 (1:1) base with 3151 mg/L D-glucose and 110 mg/L sodium pyruvate; pH 7.4 (USP <791>)
• Formulated without L-glutamine and without sodium bicarbonate — supplement L-glutamine and a buffering system (HEPES or bicarbonate) to match your culture system
• Contains phenol red (8.630 mg/L) as a visual pH indicator
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm); manufactured under an ISO 13485:2016 quality management system
• Every batch tested to USP <71> (14-day sterility) and USP <788> Method 1 (light obscuration particulate) before release
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and endotoxin variability that accumulate inside microchannels — corrupting biosensor readings, triggering inflammation in primary cultures, and shortening device lifetimes. FluxMPS™ addresses these failure modes through validated four-stage filtration.

Quadruple-stage filtration system

FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (1:1) w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid is processed through a four-stage serial filtration sequence reaching 0.04 µm — addressing mycoplasma-sized particulates, subvisible particles, and bioburden that 0.22 µm filtration alone does not retain.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates and aggregates; protects the first 0.04 µm final filter cartridge and extends filter life.

2. 2

   0.04 µm Final filtration I

   Fine particulate and bacteria retention; the pore size is smaller than the 0.2–0.3 µm mycoplasma diameter, a class of particulate not addressed by standard 0.22 µm filtration.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm final filter cartridge in this paired train.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; ISO Class 5 aseptic fill in a validated laminar-flow workstation.

Designed for next-generation cell culture platforms

FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (1:1) w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid is suited for organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate load and endotoxin variability are unacceptable.

Automated Bioreactors & Robotics

An optional MPS Grade 0.01 µm (10 nm) ultra nano-filtered variant is available for automated bioreactor and robotic perfusion systems requiring the highest particulate exclusion; this is a separate tier from the Microfluidics Suitable product on this page.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the MPS Grade 0.01 µm variant.

Lot-release quality parameters

Every production batch of FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (1:1) w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid undergoes the complete quality-release battery below before shipment.

Available pack sizes: 500 mL, 1000 mL

Full composition (mg/L)

Complete formulation with CAS numbers, reproduced from manufacturer specification. Total: 50 components across 4 categories (Inorganic Salts, Amino Acids, Vitamins, Others). Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under ISO 13485:2016 QMS with final packaging, testing, and customization at Diagnocine Precision in Totowa, New Jersey, USA.

How DCP-DM12-QBT1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered alternatives of the same base formulation.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ Dulbecco’s Modified Eagle Medium/ Ham's F-12 Nutrient Mixture (DMEM/F-12) (1:1) w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid and Microfluidics Suitable cell culture media.

Supporting literature

Peer-reviewed publications supporting Microfluidics Suitable, ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Eagle H (1959). Amino acid metabolism in mammalian cell cultures. Science, 130(3373), 432–437. doi:10.1126/science.130.3373.432
4. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
5. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
6. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
7. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539
8. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175